|
| Press Releases |
|
 |
|
| Wednesday, June 29, 2022 |
|
|
Jacobson Pharma Announces FY2022 Annual Results |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period"). more info >> |
|
| Wednesday, June 15, 2022 |
|
|
万隆、雅各臣及健倍苗苗成立合资公司 拓展大中华区及亚洲专科药及品牌医疗保健市场 |
| 万隆控股集团有限公司（「万隆」，连同其附属公司「万隆集团」; 股份代号：0030.HK），其控股股东为云南白药集团股份有限公司（证券代号000538.SHE） more info >> |
|
|
萬隆、雅各臣及健倍苗苗成立合資公司 拓展大中華區及亞洲專科藥及品牌醫療保健市場 |
| 萬隆控股集團有限公司（「萬隆」，連同其附屬公司「萬隆集團」; 股份代號：0030.HK），其控股股東為雲南白藥集團股份有限公司（證券代號000538.SHE） more info >> |
|
|
Ban Loong, Jacobson & JBM Form Joint Venture to Tap Specialty Drugs and Branded Healthcare Markets in Greater China and Asia |
| Ban Loong Holdings Limited ("Ban Loong", together with its subsidiaries, "Ban Loong Group"; stock code: 0030.HK), of which Yunnan Baiyao Group Co., Ltd. (stock code: 000538.SHE) is the controlling shareholder, Jacobson Pharma Corporation Limited ("Jacobson", together with its subsidiaries (excluding JBM Group) more info >> |
|
| Monday, March 14, 2022 |
|
|
雅各臣獲主席增持股份至超過六成 |
| 從事基礎藥物、專科藥物及品牌醫療保健產品研發、生產、市場推廣及銷售的領先企業 ─ 雅各臣科研製藥有限公司（「公司」；連同其附屬公司統稱「集團」；股份代號：2633 ) 獲集團主席岑廣業先生於二零二一年十二月十五日至二零二二年三月十四日期間 more info >> |
|
|
Jacobson Pharma's Chairman Uplifts Shareholding to Above 60% |
| Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma Corporation Limited (the "Company"; together with its subsidiaries, the "Group"; Stock Code: 2633), a leading company engaged in the research more info >> |
|
| Friday, November 26, 2021 |
|
|
雅各臣公布二零二二财年中期业绩 |
| 从事基础药物、专科药物及品牌医疗保健产品研发、生产、市场推广及销售的领先企业─雅各臣科研制药有限公司（「雅各臣」或「公司」；股份代号：2633 )今天公布公司及其附属公司（统称「集团」）截至二零二一年九月三十日止六个月（「报告期」）的中期业绩。 more info >> |
|
|
雅各臣公佈二零二二財年中期業績 |
| 從事基礎藥物、專科藥物及品牌醫療保健產品研發、生產、市場推廣及銷售的領先企業─雅各臣科研製藥有限公司（「雅各臣」或「公司」；股份代號：2633 )今天公佈公司及其附屬公司（統稱「集團」）截至二零二一年九月三十日止六個月（「報告期」）的中期業績。 more info >> |
|
|
Jacobson Pharma Announces FY2022 Interim Results |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of essential medicines more info >> |
|
| Tuesday, June 29, 2021 |
|
|
雅各臣公布二零二一财年全年业绩 |
| 从事基础药物、专科药物及品牌医疗保健品研发、生产、市场推广及销售的领先企业─雅各臣科研制药有限公司（「雅各臣」或「公司」；股份代号：2633 )今天公布公司及其附属公司（统称「集团」）于截至二零二一年三月三十一日止年度（「二零二一财年」或「报告期」）的全年业绩。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
How Do AI Workflow Automations Work?
Aug 16, 2025 00:00 HKT/SGT
|
|
|
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access
Aug 15, 2025 23:18 HKT/SGT
|
|
|
Yuexiu REIT Maintains Overall Operational Stability, Achieves Revenue of Over RMB966 Million
Aug 15, 2025 23:17 HKT/SGT
|
|
|
The 35th Food Expo opens today
Aug 15, 2025 23:16 HKT/SGT
|
|
|
Shoucheng Joins World Humanoid Robot Games - 88 Spectators Invited
Aug 15, 2025 23:06 HKT/SGT
|
|
|
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Aug 15, 2025 20:15 HKT/SGT
|
|
|
艾曲莫德入選《2025 ACG臨床指南：成人潰瘍性結腸炎》，獲強烈推薦用於中重度潰瘍性結腸炎的誘導緩解及維持緩解治療
Aug 15, 2025 20:07 HKT/SGT
|
|
|
艾曲莫德入选《2025 ACG临床指南：成人溃疡性结肠炎》，获强烈推荐用于中重度溃疡性结肠炎的诱导缓解及维持缓解治疗
Aug 15, 2025 19:56 HKT/SGT
|
|
|
OrbusNeich Records Growth in 2025 Interim Results, Revenue and Net Profit Reach US$83.6 Million and US$19.8 Million Respectively
Aug 15, 2025 19:11 HKT/SGT
|
|
|
業聚醫療2025年中期業績收入及純利雙雙增長 分別達8,360萬美元及1,980萬美元
Aug 15, 2025 18:53 HKT/SGT
|
|
|
业聚医疗2025年中期业绩收入及纯利双双增长 分别达8,360万美元及1,980万美元
Aug 15, 2025 18:10 HKT/SGT
|
|
|
RAK ICC Strengthens Foundations Regime with 2025 Legislative Enhancements
Aug 15, 2025 18:00 HKT/SGT
|
|
|
廣發証券榮膺國家數據管理能力成熟度（DCMM）最高等級認証
Aug 15, 2025 17:28 HKT/SGT
|
|
|
米国株式アクティブ残高10年連続世界No.1ティー・ロウ・プライス[1] 日本法人が既存追加型株式投資信託に「毎月決算・予想分配金提示型」ファンドを新規設定
Aug 15, 2025 17:15: JST
|
|
|
广发证券荣膺国家数据管理能力成熟度（DCMM）最高等级认证
Aug 15, 2025 17:12 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
